



Microbiota and Pathogen Proteases Modulate Type III Secretion Activity in Enterohemorrhagic *Escherichia coli*

Elizabeth A. Cameron,^{a,b,c} Meredith M. Curtis,^{a,b} Aman Kumar,^{a,b} Gary M. Dunny,^c Vanessa Sperandio^{a,b}

^aDepartment of Microbiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA

^bDepartment of Biochemistry, University of Texas Southwestern Medical Center, Dallas, Texas, USA

^cDepartment of Microbiology and Immunology, University of Minnesota, Minneapolis, Minnesota, USA

ABSTRACT Enteric pathogens have complex interactions with the gut microbiota. Most of what is known about them has focused on microbiota-derived metabolites or small molecules that serve as nutrients and/or signals to aid in growth or transcriptionally regulate virulence gene expression. A common virulence strategy is to express a type III secretion system (T3SS), which is a molecular syringe deployed by many Gram-negative pathogens to hijack host cell function. Enterohemorrhagic *Escherichia coli* (EHEC) requires its T3SS to colonize the intestinal tract and cause disease. Here we report that a prominent member of the intestinal microbiota, *Bacteroides thetaiotamicron* (*Bt*), secretes proteases that cleave the translocon of the T3SS of EHEC to enhance effector translocation into host cells. This is in contrast from an endogenous protease from EHEC itself (namely, EspP) that cleaves the translocon protein EspB in a different site to limit effector translocation. The EspB protein forms the T3SS pore in mammalian cells, and pore proteins are conserved in the T3SSs from several pathogens. This is the first demonstration of a commensal species directly processing a pathogen's T3SS, posing a new paradigm for how the microbiota can influence the severity of disease caused by bacterial pathogens. Because T3SSs are employed by many pathogens, this phenomenon has broad implications to commensal-pathogen relationships.

IMPORTANCE The gut microbiota is usually regarded as providing colonization resistance against enteric pathogens. However, some pathogens evolved to thrive with the aid of certain members of the microbiota. Several Gram-negative bacteria employ type three secretion systems (T3SSs), which are molecular syringes that deliver effector proteins to host cells, hijacking host cell function. Here we show that the T3SS of enterohemorrhagic *E. coli* (EHEC) is cleaved by self and microbiota-derived proteases. Self-cleavage limits effector translocation, while cleavage by the microbiota member *Bacteroides thetaiotamicron* (*Bt*) exacerbates effector translocation and lesion formation on epithelial cells.

KEYWORDS EspP, *Bacteroides*, enterohemorrhagic *E. coli* (EHEC), microbiota, type three secretion

Upon entering the intestinal tract, pathogenic bacteria are confronted with a densely populated ecosystem saturated with bacterial competitors. The bacterial species that comprise the microbiota can significantly affect the course of disease during an infection with an intestinal pathogen in ways that we are just beginning to understand (1). Enterohemorrhagic *Escherichia coli* (EHEC) is an enteric pathogen that colonizes the colon and causes outbreaks of bloody diarrhea and hemolytic uremic syndrome (HUS) worldwide. It causes more than 265,000 food-borne infections and more than 30 deaths each year in the United States (2). EHEC has a remarkably low infectious dose compared to those of other intestinal pathogens. As little as 10 to 100

Received 9 October 2018 Accepted 24 October 2018 Published 4 December 2018

Citation Cameron EA, Curtis MM, Kumar A, Dunny GM, Sperandio V. 2018. Microbiota and pathogen proteases modulate type III secretion activity in enterohemorrhagic *Escherichia coli*. mBio 9:e02204-18. <https://doi.org/10.1128/mBio.02204-18>.

Editor Arturo Casadevall, Johns Hopkins Bloomberg School of Public Health

Copyright © 2018 Cameron et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Vanessa Sperandio, vanessa.sperandio@utsouthwestern.edu. E.A.C. and M.M.C. contributed equally to this article.

This article is a direct contribution from a Fellow of the American Academy of Microbiology. Solicited external reviewers: Eric Skaar, Vanderbilt University; M. Stephen Trent, University of Georgia.




FIG 1 The EHEC T3SS is cleaved by self-produced and *Bacteroides thetaiotaomicron* (*Bt*)-produced proteases. (A) EHEC T3SS: EspA is a sheath around the needle that connects to the pore proteins EspBD, forming the translocon. Several effectors, one of which is Tir, are translocated to the host cell. Tir serves as the receptor for the bacterial adhesin intimin and promotes actin polymerization, leading to AE lesion formation. (B) Mass spectrometric analysis of culture supernatants. Data are presented as a ratio of protein present in supernatants from EHEC grown in the presence of *B. thetaiotaomicron* (*B theta*) to protein present in supernatants from EHEC grown alone. (C and D) Western blot analysis of endogenous EspAB levels in culture supernatants of EHEC alone or EHEC plus *Bt* cultured for 6 h (C) and 24 h (D) in *in vitro* culture. EspAB levels in culture supernatants were analyzed by Western blotting using anti-EspAB antibodies. BSA is used as a loading control. α -EspB, anti-EspB antibody. (E) qPCR of *espADB* operon. *espABD* transcript levels from EHEC cultures with or without *Bt* were normalized to *rpoA* levels and are expressed as fold change over the values for EHEC alone. (F) Endogenous EspB levels. *In vitro* culture supernatants and lysates were collected at 4, 5, and 6 hours, and EspB was analyzed by Western blotting. The positions of the 37-kDa uncleaved EspB, 34-kDa cleaved EspB (blue arrows), and 30-kDa cleaved EspB (red arrows) are indicated. ctrl, control.

organisms are sufficient to cause disease (3), suggesting that EHEC has evolved particularly effective strategies to compete and even take advantage of the resident microbes it encounters in the intestinal tract. Previous studies have shown that EHEC uses microbiota-derived molecules, such as fucose (4) and succinate (5), as signals to assess the environment and control expression of its virulence factors.

The two main virulence factors expressed by EHEC are Shiga toxin and a type III secretion system (T3SS), which is a syringe-like apparatus used to inject bacterial effectors into the host cell that either mimic or hijack host cell function (6). The EHEC T3SS is encoded on a pathogenicity island named the locus of enterocyte effacement (LEE) and is required for EHEC to colonize the intestine and cause disease (7, 8). Three LEE-encoded proteins, EspA, EspB, and EspD, form the translocon of the EHEC T3SS: EspA forms a sheath around the needle, and EspB and EspD form the pore in the host cell membrane (9, 10) (Fig. 1A). LEE-encoded and non-LEE-encoded effector proteins are injected into host cells through the translocon and interact with host proteins, leading to actin polymerization and formation of the characteristic attaching and effacing (AE) lesion, a pedestal-like structure that cups the bacterial cell. This pedestal structure promotes tight adherence of the bacterium to host cells and leads to effacement of the intestinal microvilli (11).

Expression of the LEE is modulated by a complex regulatory cascade that incorpo-

rates environmental and microbiota- and host-derived signals (12–15). However, much of this work has focused on modulation of the LEE at the transcriptional level, with less emphasis on posttranscriptional or posttranslational regulation. Even less studied is the way in which the microbiota and microbiota-derived molecules may affect virulence factors posttranscriptionally or posttranslationally. In this study, we investigated the effect of a common human commensal, *Bacteroides thetaiotamicron* (*Bt*), on the expression of T3SS-associated proteins and their functions. The presence of *Bt* affects LEE expression at the transcriptional level (4, 5), but this interaction has not been probed further to understand more fully the relationship between commensals and pathogens during the course of an infection. Here we show that EHEC- and *Bt*-secreted proteases cleave the T3SS translocon proteins. These cleavage events differentially impact T3SS function. Cleavage by EHEC's serine protease autotransporter (SPATE), EspP, limits effector translocation to host cells. Meanwhile, processing of the T3SS by *Bt* proteases promotes effector translocation, increasing AE lesion formation on epithelial cells.

RESULTS

The EHEC T3SS is cleaved by EHEC-produced and *Bt*-produced proteases. To investigate the effect of *Bacteroides thetaiotamicron* (*Bt*) on EHEC's T3SS, secreted proteins from EHEC monoculture and EHEC+*Bt* coculture were analyzed via mass spectrometry (see Table S1 and Fig. S1 in the supplemental material). We identified 37 proteins in EHEC supernatants whose levels were significantly changed, including secreted proteases, outer membrane and iron binding proteins, enzymes, and stress proteins among others. It is noticeable that EspB and EspD, two structural components of the T3SS, were decreased in the EHEC+*Bt* coculture (Fig. 1B) with an approximately 500-fold decrease in protein levels compared to EHEC alone for EspB (Fig. 1B). After six hours of growth in the presence of *Bt*, decreased EspB was observed in supernatants compared to supernatants of EHEC cultured alone (Fig. 1C), and at 24 h, EspB was not detected (Fig. 1D). The levels of EspA were unchanged in EHEC+*Bt* coculture at six hours of growth (Fig. 1C) but decreased by 24 h (Fig. 1D). However, it was previously reported that the presence of *Bt* enhances transcription of the T3SS genes (5). Indeed, transcription of *espABD* is upregulated in the presence of *Bt* (Fig. 1E), despite protein levels in supernatants being decreased, suggesting that protein levels are being modulated posttranscriptionally. To define the timing of EspB cleavage, samples from EHEC monoculture and EHEC+*Bt* coculture were collected at 4, 5, and 6 h postinoculation (p.i.), and EspB levels in supernatants and cell lysates were analyzed. At 4 h p.i., there is little EspB cleavage, and by 5 h, EspB cleavage products are visible in the coculture condition. At 6 h, cleavage of EspB occurs in the EHEC-alone condition as well as in the presence of *Bt*, where EspB levels are severely decreased. EspB cleavage occurs after secretion and is not observed in whole-cell lysates (Fig. 1F). It is noticeable that the overall levels of EspB decrease at the 6-h time point (Fig. 1F). This is probably due to the decrease in the overall transcription of the LEE genes at this time point, which is when EHEC reaches stationary phase (16).

Secreted proteases from EHEC and *Bt* differentially cleave the T3SS translocon components. An assay combining purified recombinant EspB (rEspB) with supernatants or lysates from mono- or cocultures of EHEC (EHEC Δ *espB* was used to eliminate confounding effects from endogenous EspB production) and *Bt* showed that cleavage of EspB by EHEC and *Bt* leads to distinct products. As expected, there was no EspB cleavage with cell lysates, confirming that EspB cleavage occurs by secreted EHEC and *Bt* proteases. Distinct rEspB cleavage products were observed with supernatants: EHEC supernatants yielded a 30-kDa rEspB, and *Bt* supernatants yielded 36-kDa and 34-kDa rEspBs (Fig. 2A). Protease inhibitors decreased the 30-kDa and 34-kDa rEspBs (Fig. 2A), confirming that these proteins were cleaved by EHEC- and *Bt*-derived proteases at different sites. It is noteworthy that cleavage of EspB is enhanced with the EHEC+*Bt* supernatants, compared to *Bt* supernatants alone (Fig. 2A and B). There are two potential explanations to these data; one is that EHEC enhances protease expression in *Bt*, the second is that both EHEC and *Bt* proteases act in a synergistic fashion.




FIG 2 Both EHEC and *Bt* secrete proteases targeting EspB for degradation. (A) Western blot analysis of exogenous EspB. Purified rEspB-His was incubated with either the lysate or supernatant from EHEC *ΔespB* grown alone, EHEC *ΔespB* plus *Bt*, or *Bt* grown alone. Cultures were grown for 4.5 h prior to harvest. EspB-His (1 μ g) was incubated at 37°C for 45 min in the presence or absence of a protease inhibitor cocktail (Sigma). (B) Exogenous EspB assay with serine protease inhibitors. rEspB-His (1 μ g) was incubated with supernatants from specified cultures overnight in the presence or absence of serine protease inhibitors (PMSF, aprotinin) at 37°C. O/N, overnight. (C) Mass spectrometric analysis of proteases present in culture supernatant. Data are presented as a ratio of EHEC + *Bt*/EHEC alone. (D) Western blot analysis of exogenous EspB. Purified EspB-His was incubated with supernatants from EHEC *ΔespB* grown alone, EHEC *ΔespB* plus *Bt*, EHEC *ΔespB ΔespP*, EHEC *ΔespB ΔespP* plus *Bt*, or *Bt* grown alone. Cultures were grown for 4.5 h prior to harvest. EspB-His (1 μ g) was incubated at 37°C for 45 min. DMEM medium was used as a negative control. (E) Western blot analysis of exogenous EspA. Purified EspA-His was incubated with supernatants from EHEC *ΔespA* or EHEC *ΔespA ΔespP*. (F) Western blot analysis of exogenous EspD. Purified EspD-His was incubated with supernatants from EHEC *ΔespD*, EHEC *ΔespD ΔespP*, or PBS as a negative control. Different EspB cleaved products are shown boxed in different colors: green, 36-kDa product; blue, 34-kDa product; and red, 30-kDa product.

Class-specific protease inhibitors indicated that the EHEC and *Bt* proteases that yielded the 30-kDa and 34-kDa rEspBs were serine proteases (Fig. 2B). Five EHEC-secreted proteases were identified through mass spectrometry, with two of them (StcE and EspP) encoded only in the EHEC genome, while the other three are present in both EHEC and *E. coli* K-12 (Fig. 2C). To narrow down the candidate proteases, rEspB was incubated with supernatants from *E. coli* K-12, and the related AE murine pathogen *Citrobacter rodentium*. Supernatants from neither of them gave rise to the 30-kDa rEspB (Fig. S2A), suggesting that the protease is EHEC specific and is either StcE or EspP. EHEC *ΔstcE* still cleaved EspB in the 30-kDa form (Fig. S2B), while EHEC *ΔespP* did not (Fig. 2D), showing that StcE is not the protease cleaving EspB. Moreover, Hi-Trap-benzamidine-purified EspP (Fig. S3), specifically cleaved rEspB into the 30-kDa form (Fig. S4). Hence, EspP is the EHEC protease responsible for the 30-kDa EspB product. In addition to EspB, EspP also cleaves the EspA and EspD structural components of the T3SS (Fig. 2E and F). Through mass spectrometry on the supernatants of EHEC + *Bt* cocultures, we identified a candidate *Bt* peptidase (BT_2479) in the supernatant (Fig. S5). However, a *Bt* mutant for this gene did not lose protease activity for EspB. Mutations in six other potentially secreted candidate proteases (BT_0212, BT_1312, BT_1549, BT_1879, BT_3562, and BT_3889) in the *Bt* genome similarly did not result in loss of EspB cleavage. The *Bt*

genome contains the remarkably high number of 35 putative secreted proteases (17) so it is plausible that redundant proteases are responsible for this 34-kDa cleavage product. To more directly assess the role of both EspP and *Bt* on the proteolytic cleavage of EspB, we determined the cleavage site of the 30-kDa (EspP-derived) and 34-kDa (*Bt*-derived) products of EspB via Edman sequencing. This was possible because we had determined via C-terminal His tagging of EspB that both of these cleavage events occur near the N terminus (Fig. S6A and B). Site-directed mutations of the -1 and $+1$ amino acid of each cleavage site were made (Fig. S6C), and these mutated *espB* alleles, *espB* Δ *Bt*site and *espB* Δ EspPsite, were used to complement Δ *espB* EHEC, and it was confirmed that the mutated EspB proteins were expressed at levels similar to those of wild-type (WT) EspB (Fig. S6D) and that they were no longer cleaved by their respective proteases. It is noteworthy that there is a decrease in EspB cleavage in the *espB* Δ *Bt*site strain in the presence of *Bt*. However, cleavage is not completely abrogated. This is probably due to the fact that the 36-kDa *Bt* cleavage site is intact. We could map only the 34-kDa site because we could not completely separate the 37- and 36-kDa forms of EspB for cleavage analyses (Fig. S6E).

Translocon cleavage affects T3SS function. To determine the effect of translocon proteolysis on T3SS function, we assessed the ability of WT and Δ *espP* EHEC to form AE lesions on epithelial cells in the presence or absence of *Bt*. The Δ *espP* strain had a tendency to form a higher percentage of pedestal-producing cells and pedestals per infected cell than WT, but these numbers failed to reach statistical significance (Fig. 3A to C). As previously reported, the presence of *Bt* significantly increased pedestal formation by WT EHEC (5), and this was further increased in the Δ *espP* strain (Fig. 3A to C). The T3SS translocon protein EspA forms a sheath around the T3SS needle (Fig. 1A) that can be visualized by fluorescence microscopy using an anti-EspA antiserum, and is essential for effector translocation and AE lesion formation (18). The levels of EspA during infection of epithelial cells were elevated in Δ *espP* strain compared to the WT strain both in the presence and absence of *Bt*, and the presence of *Bt* further elevated EspA filaments in both strains (Fig. 4). A similar pattern was observed when translocation of the T3SS effector Tir was measured. Tir translocation was again elevated in the Δ *espP* strain in the presence and absence of *Bt*, and the presence of *Bt* further enhanced Tir translocation in both strains (Fig. 3D). Moreover, protease inhibitors decreased Tir translocation by the WT in the presence of *Bt* (Fig. 3E). Again, although inhibition of proteases decreased Tir translocation in the presence of *Bt*, it did not restore it to the levels of translocation in the absence of *Bt*. This is probably due to the transcriptional activation of *espB* expression in the presence of *Bt* due to sensing of *Bt*-produced succinate signaling (Fig. 1E) (5). These data show that *Bt* increases T3S function both transcriptionally and posttranslationally. Consequently, the EHEC protease EspP limits, while *Bt* proteases enhance effector translocation and AE lesion formation through differential cleavage of T3SS translocon components.

DISCUSSION

Enteric pathogens interface with a dense and highly adapted gut microbiota. The microbiota is regarded as promoting colonization resistance to pathogens (19–22), and the observation that antibiotic-treated and germfree mice are more susceptible to enteric pathogens supports this hypothesis (23–29). However, certain microbiotas may lead to pathogen expansion or enhanced virulence (5, 20, 30–32). It is noteworthy that different murine microbiotas determine susceptibility to *Citrobacter rodentium*. Microbiota transplantation from susceptible mouse strains to nonsusceptible animals induced susceptibility to infection. Conversely, microbiota transplantation from resistant to susceptible animals led to resistance (33, 34). It has also been reported that susceptibility of Swedish adults to *Campylobacter jejuni* infections differed depending on the species composition of their microbiota (35). We are starting to unravel the mechanisms by which different microbiota membership can either offer resistance or aid invading pathogens.

Here we demonstrate that EHEC and a common member of the gut microbiota,




FIG 3 EspB cleavage affects T3SS function. (A) Fluorescein actin staining (FAS) analysis. HeLa cells were infected with mCherry-expressing EHEC (WT or $\Delta espP$) with or without *Bt*. At six hours postinfection, cells were washed, fixed, and stained with DAPI and FITC-phalloidin to visualize actin. Pedestals were visualized as green puncta localized with red bacteria. (B) Quantification of percent infected cells (percentage of cells with EHEC forming pedestals). **, $P < 0.01$; ***, $P < 0.001$. (C) Quantification of number of pedestals. The number of pedestals per infected cell was determined for each field, with each field containing approximately 20 cells. The averages and standard deviation across the fields ($n = 4$) are shown. **, $P < 0.01$; ***, $P < 0.001$. (D) Tir translocation assay. A TEM-1 β -lactamase system was used to measure translocation of Tir. Reporter EHEC strains express either TEM-1 β -lactamase (*bla*) as a control or a *tir-bla* fusion that will be translocated into host cells via the T3SS. HeLa cells were infected with reporter strains (WT or $\Delta espP$) with or without *Bt*. Cells were then loaded with a fluorescent β -lactam compound whose emission spectrum was altered by β -lactamase cleavage. The 460/520 emission ratio reflects the level of β -lactamase activity and therefore the level of Tir translocation into cells. *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$. (E) The Tir translocation assay described for panel D was performed using a WT EHEC reporter strain +/- *Bt* in the presence of a protease inhibitor cocktail or DMSO vehicle control. **, $P < 0.01$; ns, not significant.

Bacteroides thetaioaomicron (*Bt*), secrete proteases that cleave structural components of the EHEC T3SS. Previous studies have demonstrated that members of the microbiota can have a significant impact on colonization and virulence gene expression by intestinal pathogens (4, 5, 31, 32). However, the majority of these studies have focused on microbiota-derived metabolites or small molecules that serve as nutrients and/or signals to aid in growth or transcriptionally regulate virulence gene expression. The role of inflammation and/or respiration in the arms race between pathogens and microbiota toward niche colonization has also been extensively documented (36–38). To our knowledge, this is the first demonstration that a protease produced by a commensal bacterium can directly cleave a pathogen's T3SS, altering its function. It has been previously demonstrated that *Bt*-derived signals modulate transcription of the locus that encodes the EHEC T3SS (5) so it is clear that the interaction between this commensal and EHEC is multifaceted.

T3SSs are expressed by many Gram-negative bacteria and are a central virulence factor for several important human pathogens, including *Salmonella*, *Yersinia*, *Shigella*, and others. There is structural homology between the translocon components of T3SSs of different species, with EspB having homologs in many pathogens (39). EspB is a




FIG 4 EspB proteolysis affects EspA filament formation. EspA immunofluorescence. HeLa cells were infected with mCherry-expressing EHEC (WT or $\Delta espP$) with and without *Bt*. At 2, 4, and 6 h postinfection, cells were fixed, permeabilized, and stained for actin (blue) and EspA filaments (green). Representative images of the 6-h time point are shown (A) and the percentage of HeLa cells that contained EspA foci are quantified (B). The percentage of EspA-positive cells was quantified for 7 randomly selected fields containing 20 to 30 cells in each field, and the average and standard deviation are shown. The experiment was performed three times to ensure reproducibility. pi, postinoculation.

component of the T3SS pore formed in the host cell (10). However, how this pore assembles in the eukaryotic membrane is largely unknown. Our data suggest that maybe a cleavage event, such as the one promoted by *Bt*, may facilitate pore formation. There is precedence for this in the assembly of the protective antigen (PA) from the anthrax toxin, where a host-mediated cleavage of PA promotes PA oligomerization and pore formation (40). Therefore, proteolytic cleavage by microbiota-derived or endogenous proteases may be a factor broadly affecting T3SSs. This presents a new paradigm for how the microbiota may shape disease progression by pathogens.

MATERIALS AND METHODS

Strains, plasmids, and culture conditions. Strains and plasmids used in this study are listed in Table S2 in the supplemental material. *Bacteroides thetaiotaomicron* (*Bt*) VPI-5482 was routinely grown anaerobically overnight at 37°C in TYG medium (41). Where indicated, *Bt* cultures were concentrated 10× prior to use to more closely mimic the natural ratios of EHEC:*Bt* in the gut. WT EHEC O157:H7 strain 86-24 (42) and its isogenic mutants were routinely grown in LB. In experiments where it was desired that the type III secretion system (T3SS) be expressed, DMEM low glucose (DMEM LG), defined as DMEM with 1 g/liter glucose, was used, as these conditions have been shown to induce the T3SS (43). Anaerobic growth was performed using the GasPak EZ anaerobe container system (Becton Dickinson). HeLa cells were routinely cultured in complete DMEM (cDMEM), defined as 4.5 g/liter glucose DMEM plus 10% FBS plus penicillin/streptomycin/glutamine.

Recombinant DNA techniques. All primers used in mutant and plasmid construction can be found in Table S3.

Construction of deletion mutants. Isogenic mutants of EHEC 86-24 were created using the λ red recombination technique (44), using pKD4 to create the deletion PCR products and pCP20 to resolve the insertions. Deletions were confirmed by sequencing.

Construction of vectors for protein expression. The open reading frames of *espABD* were cloned into pET expression vectors using standard restriction digestion and ligation methods. Protein expression and purification methods are discussed below under “Exogenous rEspB proteolysis assay.”

Construction of vectors for translocation assay. For the *bla* control plasmid, the ribosome binding site and coding sequence of the *bla* gene were amplified from the pKD3 plasmid. To construct the *tir-bla* fusion, the ribosome binding site and coding region of *tir* (minus the stop codon) were amplified via PCR from the EHEC genome and fused to the coding region (minus the signal peptide) of the *bla* gene via *soe* PCR. The *bla* and *tir-bla* inserts were cloned under the control of the pBAD promoter in the pBAD33 vector using the NEB Gibson Assembly cloning kit according to the manufacturer’s instructions. Constructs were transformed into *E. coli* DH5, and candidate clones were screened and confirmed by sequencing. Sequence-confirmed constructs were then transformed into the desired strain of EHEC.

Construction of vectors for *espB* protease site mutagenesis. *espB* was cloned into the *E. coli* pACYC184 expression vector under the tet promoter using the NEB Gibson Assembly cloning kit according to the manufacturer’s instructions. Using this construct as a template, primers were designed to alter the –1 and +1 amino acids that surround the protease cleavage sites for EspP and one of the *Bt* proteases. Primers were designed according to the specifications outlined for the NEB Q5 site-directed mutagenesis kit. For the *Bt* (34-kDa) site, amino acids L31 and S32 were mutated to A, for the EspP (30-kDa) site, amino acid A80 was mutated to G and V81 was mutated to A according to the manufac-

turer's instructions. Constructs were transformed into *E. coli* DH5, and candidate clones were screened by sequencing. Sequence-confirmed constructs were then transformed into the desired strain of EHEC. Protein expression was confirmed by Western blotting for EspB.

qPCR. For *in vitro* experiments, cultures were grown to late log phase in DMEM under anaerobic conditions (6 h). RNA was extracted using the RiboPure Bacteria isolation kit according to the manufacturer's protocols (Ambion). The primers used for quantitative reverse transcription-PCR (qRT-PCR) (Table S2) were validated for amplification efficiency and template specificity. qRT-PCR was performed as previously described (14) in a one-step reaction using an ABI 7500 sequence detection system (Applied Biosystems). Data were collected using the ABI Sequence Detection 1.2 software (Applied Biosystems). C_T values for genes of interest were normalized to the values for the *rpoA* endogenous control gene and analyzed using the comparative critical threshold (C_T) method. *espABD* gene expression was presented as fold changes over the expression level of WT EHEC cultured alone. The Student's unpaired *t* test was used to determine statistical significance.

Mass spectrometry of secreted proteome. EHEC was grown in LG DMEM in the presence or absence of *Bt* for 6 h, anaerobically. For total protein identification and quantification, concentrated supernatants were loaded onto SDS-polyacrylamide gel and run just until samples entered the resolving gel. The sample was extracted from the resolving gel and submitted for LC-MS/MS analysis to the UT-Southwestern proteomics core. Spectral counts were normalized to total protein for each sample and expressed as a ratio as relative quantity in EHEC alone versus EHEC+*Bt*.

Detection of endogenous EspB cleavage products. Overnight cultures of EHEC and *Bt* were washed, and EHEC was resuspended to $1\times$ while *Bt* was resuspended to $10\times$ to mimic ratios in the gut. LG DMEM (25 ml) was inoculated 1:100 with EHEC with and without *Bt*. The cultures were incubated anaerobically for 4, 5, or 6 h. At the indicated time point, cells were spun and pellet was lysed in 8 M urea lysis buffer overnight for whole-cell lysate samples. Supernatants were collected and filtered through a 0.22- μ m filter, and a protease inhibitor cocktail was added. BSA (0.8 mg/ml) was added to supernatants prior to concentrating to serve as a concentration/loading control. Supernatants were then concentrated $125\times$ using an Amicon concentrator (Millipore) with a 10-kDa-molecular-weight cutoff. Lysate and supernatant samples were mixed with SDS-PAGE loading buffer, boiled, and run on 12% SDS-PAGE gels. Protein was transferred to a PVDF membrane, and protein was detected using a rabbit anti-EspB polyclonal antibody (1:10,000) and a goat anti-rabbit HRP-conjugated secondary antibody (1:20,000). Blots were developed using ECL reagents according to the manufacturer's instructions.

Exogenous rEspB proteolysis assay. pET expression vectors containing the open reading frames of *espA*, *espB*, and *espD* were transformed into *E. coli* BL21. Protein expression was induced with isopropyl- β -D-thiogalactopyranoside (IPTG), and proteins were purified using gravity nickel column purification. Proteins were concentrated using Amicon concentrators and were buffer exchanged into PBS (EspA and EspD) or 20 mM HEPES, 100 mM NaCl (pH 8.0) plus 10% glycerol (EspB). Supernatants were prepared by inoculating low-glucose (1 g/liter) DMEM 1:100 with overnight cultures of the indicated strains. Cultures were grown anaerobically for 6 h before cells were pelleted, and the supernatant was collected and filtered. Supernatants were concentrated $100\times$ using 10-kDa-molecular-weight cutoff Amicon concentrators (Millipore). 60 to 100 ng of recombinant protein (varied by experiment) was combined with 150 μ l concentrated supernatant and incubated at 37°C for 45 min or overnight (16 h). Samples were mixed with SDS-PAGE loading buffer to stop the proteolysis reaction and SDS-PAGE and Western blotting to visualize EspB were performed as described above for the endogenous EspB cleavage assay.

EspB N-terminal Edman sequencing. An exogenous EspB proteolysis assay was performed as described using supernatants from EHEC Δ *espB* and WT *Bt* to generate EspB proteolysis products. Reactions were run on a 12% SDS-PAGE gel to resolve EspB proteolysis products and blotted onto a PVDF membrane using CAPS blotting buffer as specified by the UC-Davis Proteomics Core protocol for preparing Edman sequencing samples. The membranes were then stained with Coomassie blue and destained before drying. Desired bands were cut out from the dried membrane and sent to the UC-Davis proteomics core for N-terminal Edman sequencing.

Fluorescent actin staining (FAS) assay. Fluorescein actin staining assays were performed as described previously (45). Briefly, HeLa cells were grown on coverslips in 12-well culture plates in cDMEM at 37°C and 5% CO₂ overnight to 80% confluence. The wells were washed with PBS and replaced with low-glucose DMEM supplemented with 10% FBS. mCherry-expressing EHEC was grown standing overnight in LB, and *Bt* cultures were grown overnight anaerobically in TYG medium. Before infection, *Bt* cultures were concentrated $10\times$ to mimic ratios in the intestinal tract. Bacterial cultures were then diluted 1:100 to infect HeLa cells for 6 h at 37°C and 5% CO₂, with media being removed and replaced at 3 h postinfection. After a 6-h infection, the coverslips were washed, fixed, permeabilized, and treated with fluorescein isothiocyanate (FITC)-labeled phalloidin to visualize actin accumulation and mounted on slides with ProLong gold antifade mountant with DAPI to visualize host nuclei. Samples were visualized with a Zeiss LSM880 confocal microscope. The percent infected cells (percentage of cells containing pedestals) and pedestals per infected cell were determined for each field with each field containing approximately 20 cells. The averages and standard deviation across the fields ($n = 4$) are displayed for one experiment.

EspA immunofluorescence. HeLa cell infections for EspA filament staining were performed as described above for the FAS assay except that coverslips were washed and fixed at 2, 4, and 6 h postinfection. After fixing and permeabilizing, cells were treated with phalloidin-Alexa Fluor 350 to visualize host actin. Cells were then treated with 1:1,000 dilution of polyclonal anti-EspA antisera in PBS for 15 min at room temperature. Cells were then washed and stained with anti-rabbit FITC-conjugated secondary antibody (Sigma) diluted 1:1,000 in PBS for 15 min. Coverslips were mounted on slides with

ProLong gold antifade and visualized with a Zeiss LSM880 confocal microscope. The percent HeLa cells with EspA-positive bacteria attached was quantified for 7 randomly selected fields containing 20 to 30 cells each, and the average and standard deviation values for the fields were calculated. The experiment was performed three times to ensure reproducibility, but the data shown are from a single experiment due to interexperimental variability.

Translocation assay. *bla* and *tir-bla* reporter constructs were created as described above and transformed into the desired strains of EHEC. To perform the assay, HeLa cells were seeded in at 1×10^4 cells per well into a black-walled, clear-bottom 96-well plate 48 h prior to infection in cDMEM. Overnight cultures of bacterial strains (WT or Δ espP EHEC with and without *B. thetaiotaomicron*) were subcultured 1:20 into 1.5-ml DMEM LG plus 5% FBS in a 12-well plate. Cultures were grown for 3 h at 37°C in 5% CO₂. The medium was removed from HeLa cells, cells were washed once with DMEM LG, and then 100 μ l DMEM LG plus 5% FBS was added to each well. HeLa cells were infected with 15 μ l of the pregrown bacterial cultures and incubated at 37°C in 5% CO₂ for 30 min. Blank (no HeLa cells) and uninfected cells were included as controls, and each experimental condition was run in triplicate. Reporter constructs were then induced by adding 0.2% arabinose (final concentration) and incubating for 1 h. The medium was then removed from the cells, cells were washed once with HBSS, and cells were loaded with freshly prepared CCF2/AM substrate according to the manufacturer's instructions using the GeneBLazer *in vivo* detection kit (Invitrogen). Results were read on a FLUOstar Optima microplate reader (BMG Labtech): readings were collected from the bottom, exciting at 405 nm and reading emission at 460 nm and 520 nm. Gain was set to 10% of blank (no HeLa cells) wells. For each well, the ratio of 460/520 nm emission was calculated, and then the average and standard deviations for the three replicate wells were calculated.

SUPPLEMENTAL MATERIAL

Supplemental material for this article may be found at <https://doi.org/10.1128/mBio.02204-18>.

FIG S1, PDF file, 0.2 MB.

FIG S2, PDF file, 0.2 MB.

FIG S3, PDF file, 0.3 MB.

FIG S4, PDF file, 0.3 MB.

FIG S5, PDF file, 0.2 MB.

FIG S6, PDF file, 0.4 MB.

TABLE S1, PDF file, 0.1 MB.

TABLE S2, PDF file, 0.3 MB.

TABLE S3, PDF file, 0.2 MB.

ACKNOWLEDGMENTS

We thank Hamid Baniyasi from the UT Southwestern Mass Spectrometry Core facility for his help in the analysis of mass spectrometry data.

This study was supported by NIH grants AI053067, AI05135, and AI114511 to V.S. E.A.C. was supported by NRSA grant F32 AI126722. M.M.C. was supported by NIH Training Grant 5 T32 AI7520-14.

E.A.C. and M.M.C. conceived the studies, performed experiments and data analysis, and wrote the paper. A.K. performed experiments and analyzed data. G.M.D. analyzed data and helped write the paper. V.S. supervised all experiments, analyzed data, and wrote the paper.

We declare that we have no competing interests.

REFERENCES

- Baumler AJ, Sperandio V. 2016. Interactions between the microbiota and pathogenic bacteria in the gut. *Nature* 535:85–93. <https://doi.org/10.1038/nature18849>.
- Scallan E, Hoekstra RM, Angulo FJ, Tauxe RV, Widdowson MA, Roy SL, Jones JL, Griffin PM. 2011. Foodborne illness acquired in the United States—major pathogens. *Emerg Infect Dis* 17:7–15. <https://doi.org/10.3201/eid1701.091101p1>.
- Tuttle J, Gomez T, Doyle MP, Wells JG, Zhao T, Tauxe RV, Griffin PM. 1999. Lessons from a large outbreak of *Escherichia coli* O157:H7 infections: insights into the infectious dose and method of widespread contamination of hamburger patties. *Epidemiol Infect* 122:185–192. <https://doi.org/10.1017/S0950268898001976>.
- Pacheco AR, Curtis MM, Ritchie JM, Munera D, Waldor MK, Moreira CG, Sperandio V. 2012. Fucose sensing regulates bacterial intestinal colonization. *Nature* 492:113–117. <https://doi.org/10.1038/nature11623>.
- Curtis MM, Hu Z, Klimko C, Narayanan S, Deberardinis R, Sperandio V. 2014. The gut commensal *Bacteroides thetaiotaomicron* exacerbates enteric infection through modification of the metabolic landscape. *Cell Host Microbe* 16:759–769. <https://doi.org/10.1016/j.chom.2014.11.005>.
- Kaper JB, Nataro JP, Mobley HL. 2004. Pathogenic *Escherichia coli*. *Nat Rev Microbiol* 2:123–140. <https://doi.org/10.1038/nrmicro818>.
- McDaniel TK, Jarvis KG, Sonnenberg MS, Kaper JB. 1995. A genetic locus of enterocyte effacement conserved among diverse enterobacterial pathogens. *Proc Natl Acad Sci U S A* 92:1664–1668. <https://doi.org/10.1073/pnas.92.5.1664>.
- Jarvis KG, Giron JA, Jerse AE, McDaniel TK, Sonnenberg MS, Kaper JB. 1995. Enteropathogenic *Escherichia coli* contains a putative type III

- secretion system necessary for the export of proteins involved in attaching and effacing lesion formation. *Proc Natl Acad Sci U S A* 92: 7996–8000. <https://doi.org/10.1073/pnas.92.17.7996>.
9. Garmendia J, Frankel G, Crepin VF. 2005. Enteropathogenic and enterohemorrhagic *Escherichia coli* infections: translocation, translocation, translocation. *Infect Immun* 73:2573–2585. <https://doi.org/10.1128/IAI.73.5.2573-2585.2005>.
 10. Ide T, Laarmann S, Greune L, Schillers H, Oberleithner H, Schmidt MA. 2001. Characterization of translocation pores inserted into plasma membranes by type III-secreted Esp proteins of enteropathogenic *Escherichia coli*. *Cell Microbiol* 3:669–679. <https://doi.org/10.1046/j.1462-5822.2001.00146.x>.
 11. Campellone KG, Leong JM. 2003. Tails of two Tirs: actin pedestal formation by enteropathogenic *E. coli* and enterohemorrhagic *E. coli* O157:H7. *Curr Opin Microbiol* 6:82–90. [https://doi.org/10.1016/S1369-5274\(03\)00005-5](https://doi.org/10.1016/S1369-5274(03)00005-5).
 12. Sperandio V, Torres AG, Jarvis B, Nataro JP, Kaper JB. 2003. Bacteria-host communication: the language of hormones. *Proc Natl Acad Sci U S A* 100:8951–8956. <https://doi.org/10.1073/pnas.1537100100>.
 13. Clarke MB, Hughes DT, Zhu C, Boedeker EC, Sperandio V. 2006. The QseC sensor kinase: a bacterial adrenergic receptor. *Proc Natl Acad Sci U S A* 103:10420–10425. <https://doi.org/10.1073/pnas.0604343103>.
 14. Hughes DT, Clarke MB, Yamamoto K, Rasko DA, Sperandio V. 2009. The QseC adrenergic signaling cascade in enterohemorrhagic *E. coli* (EHEC). *PLoS Pathog* 5:e1000553. <https://doi.org/10.1371/journal.ppat.1000553>.
 15. Reading NC, Rasko DA, Torres AG, Sperandio V. 2009. The two-component system QseEF and the membrane protein QseG link adrenergic and stress sensing to bacterial pathogenesis. *Proc Natl Acad Sci U S A* 106:5889–5894. <https://doi.org/10.1073/pnas.0811409106>.
 16. Sperandio V, Mellies JL, Nguyen W, Shin S, Kaper JB. 1999. Quorum sensing controls expression of the type III secretion gene transcription and protein secretion in enterohemorrhagic and enteropathogenic *Escherichia coli*. *Proc Natl Acad Sci U S A* 96:15196–15201. <https://doi.org/10.1073/pnas.96.26.15196>.
 17. Xu J, Bjursell MK, Himrod J, Deng S, Carmichael LK, Chiang HC, Hooper LV, Gordon JI. 2003. A genomic view of the human-Bacteroides thetaiotaomicron symbiosis. *Science* 299:2074–2076. <https://doi.org/10.1126/science.1080029>.
 18. Knutton S, Rosenshine I, Pallen MJ, Nisan I, Neves BC, Bain C, Wolff C, Dougan G, Frankel G. 1998. A novel EspA-associated surface organelle of enteropathogenic *Escherichia coli* involved in protein translocation into epithelial cells. *EMBO J* 17:2166–2176. <https://doi.org/10.1093/emboj/17.8.2166>.
 19. Sassone-Corsi M, Raffatellu M. 2015. No vacancy: how beneficial microbes cooperate with immunity to provide colonization resistance to pathogens. *J Immunol* 194:4081–4087. <https://doi.org/10.4049/jimmunol.1403169>.
 20. Cameron EA, Sperandio V. 2015. Frenemies: signaling and nutritional integration in pathogen-microbiota-host interactions. *Cell Host Microbe* 18:275–284. <https://doi.org/10.1016/j.chom.2015.08.007>.
 21. Pacheco AR, Sperandio V. 2015. Enteric pathogens exploit the microbiota-generated nutritional environment of the gut. *Microbiol Spectr* 3(3). <https://doi.org/10.1128/microbiolspec.MBP-0001-2014>.
 22. Bohnhoff M, Drake BL, Miller CP. 1954. Effect of streptomycin on susceptibility of intestinal tract to experimental *Salmonella* infection. *Proc Soc Exp Biol Med* 86:132–137. <https://doi.org/10.3181/00379727-86-21030>.
 23. Ferreira RB, Gill N, Willing BP, Antunes LC, Russell SL, Croxen MA, Finlay BB. 2011. The intestinal microbiota plays a role in *Salmonella*-induced colitis independent of pathogen colonization. *PLoS One* 6:e20338. <https://doi.org/10.1371/journal.pone.0020338>.
 24. Nardi RM, Silva ME, Vieira EC, Bambirra EA, Nicoli JR. 1989. Intra-gastric infection of germfree and conventional mice with *Salmonella typhimurium*. *Braz J Med Biol Res* 22:1389–1392.
 25. Sekirov I, Tam NM, Jogova M, Robertson ML, Li Y, Lupp C, Finlay BB. 2008. Antibiotic-induced perturbations of the intestinal microbiota alter host susceptibility to enteric infection. *Infect Immun* 76:4726–4736. <https://doi.org/10.1128/IAI.00319-08>.
 26. Sprinz H, Kundel DW, Dammin GJ, Horowitz RE, Schneider H, Formal SB. 1961. The response of the germfree guinea pig to oral bacterial challenge with *Escherichia coli* and *Shigella flexneri*. *Am J Pathol* 39: 681–695.
 27. Wlodarska M, Willing B, Keeney KM, Menendez A, Bergstrom KS, Gill N, Russell SL, Vallance BA, Finlay BB. 2011. Antibiotic treatment alters the colonic mucus layer and predisposes the host to exacerbated *Citrobacter rodentium*-induced colitis. *Infect Immun* 79:1536–1545. <https://doi.org/10.1128/IAI.01104-10>.
 28. Zachar Z, Savage DC. 1979. Microbial interference and colonization of the murine gastrointestinal tract by *Listeria monocytogenes*. *Infect Immun* 23:168–174.
 29. Kamada N, Kim YG, Sham HP, Vallance BA, Puente JL, Martens EC, Nunez G. 2012. Regulated virulence controls the ability of a pathogen to compete with the gut microbiota. *Science* 336:1325–1329. <https://doi.org/10.1126/science.1222195>.
 30. Yurist-Doutsch S, Arrieta MC, Vogt SL, Finlay BB. 2014. Gastrointestinal microbiota-mediated control of enteric pathogens. *Annu Rev Genet* 48:361–382. <https://doi.org/10.1146/annurev-genet-120213-092421>.
 31. Ferreyra JA, Wu KJ, Hryckowian AJ, Bouley DM, Weimer BC, Sonnenburg JL. 2014. Gut microbiota-produced succinate promotes *C. difficile* infection after antibiotic treatment or motility disturbance. *Cell Host Microbe* 16:770–777. <https://doi.org/10.1016/j.chom.2014.11.003>.
 32. Ng KM, Ferreyra JA, Higginbottom SK, Lynch JB, Kashyap PC, Gopinath S, Naidu N, Choudhury B, Weimer BC, Monack DM, Sonnenburg JL. 2013. Microbiota-liberated host sugars facilitate post-antibiotic expansion of enteric pathogens. *Nature* 502:96–99. <https://doi.org/10.1038/nature12503>.
 33. Ghosh S, Dai C, Brown K, Rajendiran E, Makarenko S, Baker J, Ma C, Halder S, Montero M, Ionescu VA, Klegeris A, Vallance BA, Gibson DL. 2011. Colonic microbiota alters host susceptibility to infectious colitis by modulating inflammation, redox status, and ion transporter gene expression. *Am J Physiol Gastrointest Liver Physiol* 301:G39–G49. <https://doi.org/10.1152/ajpgi.00509.2010>.
 34. Willing BP, Vacharaksa A, Croxen M, Thanachayanont T, Finlay BB. 2011. Altering host resistance to infections through microbial transplantation. *PLoS One* 6:e26988. <https://doi.org/10.1371/journal.pone.0026988>.
 35. Kampmann C, Dicksved J, Engstrand L, Rautelin H. 2015. Composition of human faecal microbiota in resistance to *Campylobacter* infection. *Clin Microbiol Infect* 22:e1–e8. <https://doi.org/10.1016/j.cmi.2015.09.004>.
 36. Winter SE, Thiennimitr P, Winter MG, Butler BP, Huseby DL, Crawford RW, Russell JM, Bevins CL, Adams LG, Tsois RM, Roth JR, Baumler AJ. 2010. Gut inflammation provides a respiratory electron acceptor for *Salmonella*. *Nature* 467:426–429. <https://doi.org/10.1038/nature09415>.
 37. Winter SE, Winter MG, Xavier MN, Thiennimitr P, Poon V, Keestra AM, Laughlin RC, Gomez G, Wu J, Lawhon SD, Popova IE, Parikh SJ, Adams LG, Tsois RM, Stewart VJ, Baumler AJ. 2013. Host-derived nitrate boosts growth of *E. coli* in the inflamed gut. *Science* 339:708–711. <https://doi.org/10.1126/science.1232467>.
 38. Faber F, Thiennimitr P, Spiga L, Byndloss MX, Litvak Y, Lawhon S, Andrews-Polymeris HL, Winter SE, Baumler AJ. 2017. Respiration of microbiota-derived 1,2-propanediol drives *Salmonella* expansion during colitis. *PLoS Pathog* 13:e1006129. <https://doi.org/10.1371/journal.ppat.1006129>.
 39. Deng W, Marshall NC, Rowland JL, McCoy JM, Worrall LJ, Santos AS, Strynadka NCJ, Finlay BB. 2017. Assembly, structure, function and regulation of type III secretion systems. *Nat Rev Microbiol* 15:323–337. <https://doi.org/10.1038/nrmicro.2017.20>.
 40. Young JA, Collier JR. 2002. Attacking anthrax. *Sci Am* 286:48–50, 54–49. <https://doi.org/10.1038/scientificamerican0302-48>.
 41. Betian HG, Linehan BA, Bryant MP, Holdeman LV. 1977. Isolation of a cellulolytic *Bacteroides* sp. from human feces. *Appl Environ Microbiol* 33:1009–1010.
 42. Griffin PM, Ostroff SM, Tauxe RV, Greene KD, Wells JG, Lewis JH, Blake PA. 1988. Illnesses associated with *Escherichia coli* O157:H7 infections. A broad clinical spectrum. *Ann Intern Med* 109:705–712. <https://doi.org/10.7326/0003-4819-109-9-705>.
 43. Njoroge JW, Nguyen Y, Curtis MM, Moreira CG, Sperandio V. 2012. Virulence meets metabolism: Cra and KdpE gene regulation in enterohemorrhagic *Escherichia coli*. *mBio* 3:e00280-12. <https://doi.org/10.1128/mBio.00280-12>.
 44. Datsenko KA, Wanner BL. 2000. One-step inactivation of chromosomal genes in *Escherichia coli* K-12 using PCR products. *Proc Natl Acad Sci U S A* 97:6640–6645. <https://doi.org/10.1073/pnas.120163297>.
 45. Knutton S, Baldwin T, Williams PH, McNeish AS. 1989. Actin accumulation at sites of bacterial adhesion to tissue culture cells: basis of a new diagnostic test for enteropathogenic and enterohemorrhagic *Escherichia coli*. *Infect Immun* 57:1290–1298.